Stocks and Investing
Stocks and Investing
Thu, March 21, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Bill Maughan Reiterated (BNTX) at Strong Buy and Held Target at $171 on, Mar 21st, 2024
Bill Maughan of Canaccord Genuity, Reiterated "BioNTech SE" (BNTX) at Strong Buy and Held Target at $171 on, Mar 21st, 2024.
Bill has made no other calls on BNTX in the last 4 months.
There are 3 other peers that have a rating on BNTX. Out of the 3 peers that are also analyzing BNTX, 1 agrees with Bill's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chris Shibutani of "Goldman Sachs" Maintained at Hold with Decreased Target to $100 on, Wednesday, February 28th, 2024
These are the ratings of the 2 analyists that currently disagree with Bill
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $107 on, Tuesday, January 23rd, 2024
- Jessica Fye of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $99 on, Friday, December 1st, 2023
Contributing Sources